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Background: Bacterial biofilms are known to have high antibiotic tolerance which
directly affects clearance of bacterial infections in people with cystic fibrosis (CF). Current
antibiotic susceptibility testing methods are either based on planktonic cells or do not
reflect the complexity of biofilms in vivo. Consequently, inaccurate diagnostics affect
treatment choice, preventing bacterial clearance and potentially selecting for antibiotic
resistance. This leads to prolonged, ineffective treatment.
Methods: In this study, we use an ex vivo lung biofilm model to study antibiotic tolerance
and virulence of Pseudomonas aeruginosa. Sections of pig bronchiole were dissected,
prepared and infected with clinical isolates of P. aeruginosa and incubated in artificial
sputum media to form biofilms, as previously described. Then, lung-associated biofilms
were challenged with antibiotics, at therapeutically relevant concentrations, before their
bacterial load and virulence were quantified and detected, respectively.
Results: The results demonstrated minimal effect on the bacterial load with
therapeutically relevant concentrations of ciprofloxacin and meropenem, with the latter
causing an increased production of proteases and pyocyanin. A combination of
meropenem and tobramycin did not show any additional decrease in bacterial load but
demonstrated a slight decrease in total proteases and pyocyanin production.
Conclusion: In this initial study of six clinical isolates of P. aeruginosa showed high levels
of antibiotic tolerance, with minimal effect on bacterial load and increased proteases
production, which could negatively affect lung function. Thus, the ex vivo lung model
has the potential to be effectively used in larger studies of antibiotic tolerance in
in vivo-like biofilms, and show how sub optimal antibiotic treatment of biofilms may
potentially contribute to exacerbations and eventual lung failure. We demonstrate a
realistic model for understanding antibiotic resistance and tolerance in biofilms clinically
and for molecules screening in anti-biofilm drug development.
Keywords: antibiotic susceptibility testing, antimicrobial resistance, bacterial biofilm, cystic fibrosis, antibiotic
tolerance
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INTRODUCTION
Cystic fibrosis (CF) is a genetic disease in which people have
decreased mucociliary clearance in the respiratory tract, due to
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene, which encodes a chloride channel
(Davies, 2002; Lyczak et al., 2002). This impairment leads
to a reduction in mucus clearance and increased viscosity,
resulting in accumulation of microbial cells, increased bacterial
adherence and inflammation and the formation of bacterial
biofilm (Davies, 2002; Lyczak et al., 2002; Hoiby et al.,
2010). Biofilm infections are more difficult to eradicate due
to the difference in their nature compared to non-biofilm
infections; thus, they are lifelong infections in CF. These
biofilm infections are characterized by acquiring distinctive
resistance mechanisms compared with non-biofilm infections.
There are three main mechanisms. First, there may be low
antibiotic penetration into the biofilm due to the production of
extracellular matrix. Second, the different bacterial metabolic
states in the biofilm lead to increased phenotypic heterogeneity,
affecting the success of treatment. Third, adaptive mechanisms
controlling differential gene expression of multiple virulence
factors, such as efflux pumps and antibiotic-degrading
enzymes, lead to antibiotic tolerance (Breidenstein et al.,
2011; Taylor et al., 2014). The latter is highly dependent and
varies based on the environment surrounding the biofilm
(Breidenstein et al., 2011).
In CF and other biofilm-based infections, antibiotic
prescription is mainly based on standard minimum inhibitory
concentration (MIC) methods, despite these being based
on planktonic cells (Bjarnsholt et al., 2013). The current
antimicrobial susceptibility testing using planktonic-based
diagnostics are suitable for detecting intrinsic and acquired stable
resistance mechanisms; however, biofilm-based diagnostics
will additionally detect environmentally induced and biofilm-
associated resistance mechanisms. There is a drastic increase in
antibiotic tolerance using biofilm-based diagnostics, such as the
Calgary device, in comparison to MIC methods, demonstrating
the limitation of using planktonic-based models for biofilm
infections (Macia et al., 2014). Some of these in vitro biofilm
models are robust for antibiotic susceptibility screening;
they fail to recapitulate the complexity of biofilm infections,
environment and host-dependent interactions (Bjarnsholt
et al., 2013; Musken et al., 2017). All these factors affect the
antibiotic susceptibility profile (Musken et al., 2017). Also,
these biofilm models have not been developed to demonstrate
antibiotic susceptibility profile in multi-species infections. Thus,
if diagnostic tests fail to accurately detect in vivo antibiotic
resistance, this will result in recurrent and complicated infections
(Musken et al., 2017), and may lead to a vicious cycle of
increased resistance.
In this study, we employed a previously developed ex vivo
pig lung biofilm model (EVPL) (Harrison et al., 2014; Harrison
and Diggle, 2016) for antibiotic susceptibility testing of CF
P. aeruginosa isolates and compared it with standard MIC and
the Calgary device assays. The effect of exposure to antibiotics on
the virulence of P. aeruginosa was also assessed to demonstrate
the clinical effect. Ciprofloxacin and meropenem were chosen
as examples of clinically relevant antibiotic to which our CF
isolates were either all classified as resistant (ciprofloxacin) or
sensitive (meropenem) by standard planktonic MIC testing.
Tobramycin was chosen as it is clinically combined with
meropenem. The results demonstrated an increased antibiotic
tolerance in the EVPL model at concentrations >25-fold the
reported sputum concentrations when tested in Mueller-Hinton
broth, which even further increased when tested in artificial
sputum media. We also investigated the effect of exposure to
antibiotics on bacterial virulence. Exposure to antibiotics showed
an increased production of total proteases, which may have a role
in lung damage. Normalized proteases/cfu and pyocyanin/cfu
demonstrated an increased production of these virulence factors
per cell. Current clinical prognosis in CF is alarming and creates
an urgent need to develop effective anti-biofilm agents. Thus,
we propose a unique approach to predict the true clinical effect
of antibiotic treatments on bacterial clearance and associated
virulence factors in CF using the EVPL model.
MATERILS AND METHODS
Bacterial Isolates
Six clinical CF Pseudomonas aeruginosa isolates were used in this
study, selected from a set of 44 isolates from a single sputum
sample as they showed a range of phenotypes in in vitro assays
(Darch et al., 2015). PA14 was used as a control laboratory
strain for comparison.
Antibiotic Susceptibility Testing
Minimum inhibitory concentrations were performed according
to the EUCAST guidelines (EUCAST, 2019). Briefly, bacterial
isolates were cultured on Luria-Bertani (LB) agar overnight at
37◦C, resuspended in Mueller-Hinton broth (MHB) to OD600
of 0.5 and diluted 1000 times. Meropenem (Sigma-Aldrich) and
ciprofloxacin (Thermo Fisher) were two-fold serially diluted in
MHB (256–0.0156 µg/mL), to a final volume of 50 µL in a 96-
well plate (Corning). 50 µL of the diluted bacterial suspension
(5 × 105 cfu/mL final concentration) was added to all wells
and incubated for 18 h at 37◦C before the minimum inhibitory
concentrations were determined.
Minimum biofilm eradication and inhibitory concentrations
(MBEC and MBIC, respectively) were performed using Calgary
device (peg lids biofilm assay) according to Moskowitz et al.
(2004). Briefly, 100 µL of bacterial suspensions at 0.5 McFarland
were aliquoted in U shaped 96-well plates (Corning), covered
with peg lids (Thermo Electron) and incubated for 20 h at 37◦C
to form biofilms on the pegs. Peg lids were then washed three
times in sterile phosphate-buffered saline (PBS), transferred to
96-well antibiotic challenge plates containing 100 µL of 2-fold
serially diluted meropenem or ciprofloxacin (128–0.25 µg/mL)
and incubated for 18 h at 37◦C. Peg lids were washed three times
in sterile PBS, transferred to 96-well recovery plates containing
100 µL MHB and sonicated for 5 min. Peg lids were replaced
with standard plate lids, measured for absorbance at 600 nm and
incubated for 6 h at 37◦C before checked for turbidity and OD600.
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Antibiotic Tolerance in EVPL
Dissection and infection of pig lungs were performed as
described in Harrison et al. (Harrison and Diggle, 2016).
Briefly, pig bronchioles were dissected, UV sterilized (using
a Carlton germicidal cabinet with a G8T5-8 watt germicidal
tube, generating shortwave ultra-violet radiation of 2537 å) and
transferred to 24-well plates with 400 µL of 0.8% agarose/ASM
[Artificial Sputum Medium (Palmer et al., 2007)] as a pad.
Each bronchiole tissue was infected with the bacterial isolates
using a sterile syringe then 500 µL of ASM were added to
each well. Uninfected bronchiole tissues were used as negative
controls. Plates were then covered with UV sterilized breathable
membranes (Sigma-Aldrich) and incubated at 37◦C for 7 days.
Tissues were then washed in 500 µL of PBS, transferred to sterile
bead tubes containing 1 gm of metal beads (2.4 mm, Fisher
Scientific) and 1 mL of PBS, and homogenized using a FastPrep-
24TM 5G homogenizer (MP Biomedicals) for 40 s at 4.0 m/sec.
Biofilm homogenate was transferred to 96-well plates, serially
diluted 10-fold and plated on LB agar plates for calculating the
bacterial load.
For assessing the effect of different media, replicate infected
tissues were treated with antibiotics by transferring the
washed infected tissues to 48-well plates containing 300 µL
of either MHB or ASM containing ciprofloxacin (Thermo
Fisher), meropenem (Sigma), tobramycin (Thermo Fisher)
or combination therapy at the specified concentrations and
incubated at 37◦C for 24 h. Antibiotic-treated tissues were then
washed, homogenized and plated as previously described.
Determination of Virulence Factors
Production
Total proteases were quantified according to Harrison et al.
(2014). Briefly, 100µL of tissue homogenate or surrounding ASM
were added to 900 µL of azocasein solution (final concentration
of 5 mg/mL dissolved in 100 mM Tris–HCl, 1 mM CaCl2) in a
2 mL tube and incubated for 15 min at 37◦C with shaking at
170 rpm. Then, 500 µL of 10% trichloroacetic acid were added
as a stopping solution, and tubes were centrifuged at 13,000 rpm
for 1 min at room temperature. 200 µL of the supernatant were
transferred into a clean 96-well plate and the absorbance was
measured at 400 nm. PBS was used as a negative control and a
standard curve using proteinase K (Supplementary Figure S1)
was used to estimate the total amount of proteases.
Total pyocyanin was quantified according to Saha et al. (2008)
with minor modifications. Briefly, pyocyanin was extracted using
chloroform in a ratio of 5:3. The chloroform mixture was
vortexed for 2 min, then centrifuged at room temperature at
10,000 rpm for 5 min. The bottom layer was transferred to a new
2 mL tube and an equal volume of 0.2 M HCl was added. Tubes
were vortexed for 2 min, centrifuged at room temperature at
10,000 rpm for 5 min and 200 µL of the top phase was transferred
to a black 96-well plate and the absorbance was measured at
520 nm (Saha et al., 2008). The concentration of pyocyanin
(µg/mL) was calculated by multiplying the OD520 by 17.072
(Essar et al., 1990).
Statistical Analyses
All data were analyzed by ANOVA to test for the main effect and
interactions of different lung, strains and antibiotic treatments
using RStudio v1.1.463 (2009-2018 RStudio, Inc.). Unpaired
t-tests were performed for pairwise statistical analysis using
GraphPad Prism (v8.0.1) and the familywise error rate correction
for multiple comparisons.
RESULTS
Antibiotic Susceptibility Testing
Clinical P. aeruginosa strains were resistant to ciprofloxacin (MIC
2 µg/mL) and sensitive to meropenem (MIC ≤ 0.25 µg/mL)
by standard antibiotic susceptibility testing using the broth
dilution method; PA14 was sensitive to both antibiotics (Table 1).
Determination of MBECs for clinical isolates using the Calgary
device demonstrated an increase of 2–4-fold and 64–128-fold
MIC for ciprofloxacin and meropenem, respectively (Table 1).
Determination of MBICs for clinical isolates demonstrated an
increase of 4–8-fold and 64–512-fold MIC for ciprofloxacin
and meropenem, respectively (Table 1). Additionally, the MBEC
recovery plates showed no visible production of pyocyanin,
pyochelin or pyoverdine (Supplementary Figure S2).
Increased Antibiotic Tolerance of
Bacterial Biofilms in the EVPL
Figure 1 represents a schematic diagram of the work flow as
previously described. Supplementary Figures S3, S4 show pieces
of tissues infected with P. aeruginosa strains after 7 days of biofilm
TABLE 1 | Determination of MIC, MBEC, and MBIC of P. aeruginosa isolates against ciprofloxacin and meropenem.
Strains MIC (µg/mL) (n = 4) MBEC (µg/mL) (n = 4) MBIC (µg/mL) (n = 4)
Ciprofloxacin S ≤ 0.5, R > 0.5 Meropenem S ≤ 2, R > 8 Ciprofloxacin Meropenem Ciprofloxacin Meropenem
SED 20 2 0.0625 8 8 16 16
SED 29 2 0.25 4 16 16 16
SED 34 2 0.25 4 16 8 32
SED 38 2 0.0625 4 8 8 32
SED 41 2 0.125 4 16 8 16
SED 43 2 0.125 8 16 16 16
PA14 0.25 0.25 1 0.5 16 8
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FIGURE 1 | Schematic diagram of the work flow for the determination of the antibiotic susceptibility. Pig bronchioles were infected with P. aeruginosa clinical strains,
incubated to form biofilms and homogenized for the determination of the biofilm bacterial load. Replicate infected tissues were exposed to antibiotics for 24 h before
the decrease in bacterial load was determined.
formation and the mucoid phenotype of the strains in the tissues,
respectively, to represent chronic CF infection (Harrington et al.,
2020). Our previous work with the EVPL model confirms that
P. aeruginosa forms structured biofilms in this model [Alcian
blue staining confirms presence of exopolysaccharide matrix, and
mutant studies showed formation of structured aggregates on
tissue required the gacS/gacA pathway and pel polysaccharide
(Harrington et al., 2020)].
The effect of antibiotics on the bacterial load was first
tested by transferring bronchiole sections containing developed
biofilms to MHB (standard medium for microdilution assays)
containing antibiotics. This allowed to directly compare the
inhibitory effect of these antibiotics in EVPL versus in standard
diagnostics assays, without the effect of the medium or any
physiological differences induced by CF lung mucus. Treatment
with ciprofloxacin at 32-fold MIC (8–16-fold MBEC) resulted
in a 1–2 log decrease in bacterial load across all tested clinical
strains (Figure 2A). However, exposure to meropenem at 256–
1024-fold MIC (4–8-fold MBEC) resulted in only about 1 log
decrease of the bacterial load across all strains except SED 34,
which showed less than a log decrease in the bacterial count
(Figure 2B). ANOVA showed a significant effect of ciprofloxacin
[F(1,69) = 749.5, p < 0.001] and meropenem treatment
[F(1,69) = 115.5, p < 0.001] on bacterial load, the magnitude
of which was strain dependent [strain × treatment interaction
F(6,69) = 3.1, p < 0.01] for ciprofloxacin but strain independent
for meropenem [strain × treatment interaction F(6,69) = 0.71,
p = 0.64] despite the differences in MICs and MBECs.
To investigate the effect of the environment on antibiotic
tolerance, the bacterial load of the clinical isolate SED 43
was compared with and without ciprofloxacin or meropenem
in MHB and ASM: a chemically defined medium which
mimics the chemistry of chronically infected CF sputum
(Palmer et al., 2007; Figure 3). As shown in Figure 3,
there was a statistically significant increase in tolerance to
both ciprofloxacin and meropenem treatment in ASM (0.84
and 0.54 log decrease) compared with MHB (1.68 and 1.02
log decrease). ANOVA showed significant effects of changing
of medium [F(1,20) = 9.04, p < 0.01], antibiotic treatment
[F(1,20) = 44.66, p < 0.001], and a medium × antibiotic
interaction F(1,20) = 5.56, p < 0.05.
The Effect of Antibiotic-Mediated
Virulence
To understand the effect of antibiotics on the virulence of
P. aeruginosa strains, PA14 and three clinical isolates (SED 20,
SED 41, and SED 43) were assessed for the production of two
readily quantifiable and well-studied virulence factors, proteases
and pyocyanin in the lung tissues homogenate and surrounding
ASM, separately, in the presence and absence of antibiotics. In
this work, we compared our results to P. aeruginosa infected
untreated tissues and all data were normalized to uninfected
untreated tissues to show the effects that are due to antibiotics’
exposure. The ASM surrounding tissue sections at the end
of antibiotic exposure remained visibly clear, suggesting that
bacterial cells did not detach from the biofilm or grow in
the surrounding ASM at appreciable rates. Total proteases and
pyocyanin were shown to be mainly released from the biofilm
into the ASM, with a similar pattern in the tissues (Figures 4A,B).
The control strain, PA14, showed the highest protease production
(63.95–76.22 µg/mL in ASM), while clinical isolates SED 20
and SED 41 showed increased total proteases from 38.87 to
50.86 and 27.24 to 43.15 µg/mL, respectively, with meropenem
treatment (Figure 4A). Interestingly, pyocyanin production
varied between clinical strains with meropenem treatment.
SED 20 and SED 43 infected tissues demonstrated decreased
production by 68% in comparison to untreated, while SED 41
showed increased pyocyanin secretion by 162% with exposure
to meropenem (Figure 4B and Supplementary Tables S1, S2).
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FIGURE 2 | Bacterial load of P. aeruginosa in the EVPL biofilm model with and without exposure to (A) ciprofloxacin (CIP), (B) meropenem (MEM) 64 (µg/mL). The
data in red and black represents two independent lungs where closed data points are for untreated bacterial strains and open data points are for antibiotic treated.
Error bars are means ± SD, some error bars are too small to be visible on the graph. Unpaired t-tests were performed for the pairwise statistical analysis of treated
against untreated bacterial biofilm load for each strain; significant difference (p value < 0.05) are denoted with *.
Surprisingly, ciprofloxacin treatment also showed a significantly
higher pyocyanin by 116% (Figure 4B and Supplementary
Table S2). Proteases and pyocyanin concentrations in tissue
and surrounding ASM, and total fold increases associated
with antibiotic treatments are summarized in Supplementary
Tables S1, S2, respectively.
ANOVA showed a significant effect of strain [F(4,20) = 6.798,
p < 0.01] and meropenem treatment [F(1,20) = 6.519, p < 0.05]
on proteases production in the tissues, and the effect of
meropenem did not differ between strains [strain × treatment
interaction F(4,20) = 0.825, p = 0.52]. In the surrounding
ASM, similar effects were observed with strain [F(4,20) = 20.92,
p < 0.001] and meropenem treatment [F(1,20) = 3.193,
p < 0.1]. Total pyocyanin produced in the tissues and ASM
was also significantly different between strains [F(4,20) = 5.03,
p < 0.01 and F(4,20) = 6.40, p < 0.01, respectively], and
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FIGURE 3 | The effect of medium used (MHB or ASM) on antibiotic susceptibility of the clinical isolate SED 43 after exposure to ciprofloxacin (CIP) or meropenem
(MEM) at 64 (µg/mL) in the EVPL biofilm. CTRL are controls of non-treated tissues from the same lung. Error bars are means ± SD, some error bars are too small to
be visible on the graph. Unpaired t-tests were performed for the pairwise statistical analysis of treated against untreated bacterial biofilm load; significant difference (p
value < 0.05) are denoted with *.
the effect of meropenem significantly differed between strains
[strain× treatment interaction F(4,20) = 3.31, p < 0.05].
To further assess the potential effects on virulence of different
clinically relevant antibiotics, we exposed EVPL biofilms of strain
SED 43 to ciprofloxacin, tobramycin and a combination of
meropenem and tobramycin, in ASM. Isolates are resistant to
tobramycin (Darch et al., 2015). Interestingly, SED 43 showed
a greater total production of proteases, in ASM, compared
with the other clinical isolates (50.91 µg/mL), and slightly
increased total proteases with meropenem (54.85 µg/mL, 109%)
and tobramycin at low concentration (67.24 µg/mL, 133%).
Both treatments led to comparable decreases in bacterial load
(Supplementary Figure S5). The increased bacterial death
with ciprofloxacin and tobramycin, at high concentration,
(Supplementary Figure S5) correlated with decreased total
proteases of 37.55 µg/mL (74%) and 39.7 µg/mL (77%),
respectively. Combination treatment of tobramycin at 4 or
200 µg/mL with meropenem (64 µg/mL) showed a total
protease of 33.83 (62%) and 31.07 µg/mL (59%) (Figure 4A and
Supplementary Table S2), respectively.
As the total concentrations of proteases and pyocyanin
discussed above are a function of both altered cellular production
levels and altered cell numbers, we then normalized total
proteases and pyocyanin concentrations by bacterial counts, to
determine how antibiotic exposure affected per-cell production.
The amount of proteases/cfu and pyocyanin/cfu measured
in the tissues were slightly lower or equal to that of the
surrounding ASM, respectively (Figures 4C,D). Exposure
to meropenem (64 µg/mL), ciprofloxacin (64 µg/mL), and
tobramycin (4 µg/mL) slightly increased the production of
proteases and pyocyanin by bacterial cfu, while a significant
increase was found with tobramycin (200 µg/mL) and a
combination of meropenem/tobramycin (64/200 µg/mL)
(Figures 4C,D). The latter treatments have a greater effect on
bacterial load (Supplementary Figure S5). The total amount of
tissue and ASM proteases/cfu and pyocyanin/cfu is shown in
Supplementary Figure S6.
ANOVA analysis showed a significant effect of antibiotic
treatment on the amount of protease/cfu [tissue F(6,13) = 11.27,
p < 0.001] and [surrounding ASM F(6,13) = 37.09, p < 0.001],
and production of pyocyanin [tissue F(6,13) = 25.61, p < 0.001]
and [surrounding ASM F(6,13) = 17.88, p < 0.001].
DISCUSSION
In CF, chronic P. aeruginosa infections are characterized
by the mucoid phenotype, which can adversely affect the
individuals’ pulmonary function increasing mortality rates.
Therefore, oral and nebulized ciprofloxacin and colistin,
respectively, are administered at early infection stages to
reduce the risk of chronic infection and during chronic
infections to eradicate P. aeruginosa (Trust, 2009). Un-cleared
infections and moderate to severe exacerbation cases are
treated with intravenous anti-pseudomonal antibiotics such as
ceftazidime, meropenem and tobramycin in combination with
β-lactams (Trust, 2009). Pharmacokinetic characterization of
oral ciprofloxacin administration in CF has shown a Cmax of
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FIGURE 4 | Using the EVPL model for understanding bacterial virulence with and without antibiotics in comparison to control lab strains. (A) Total protease, (B) Total
pyocyanin, (C) The amount of protease/CFU, (D) The amount of pyocyanin/CFU. CIP (ciprofloxacin), MEM (meropenem) at 64 µg/mL, TOB4 and TOB200
(tobramycin at 4 and 200 µg/mL, respectively). Error bars are means ± SD, some error bars are too small to be visible on the graph.
2.3 µg/mL in sputum (Reed et al., 1988). The administration of
a single intravenous dose of meropenem (1 gm) has been shown
to achieve a bronchial secretion concentration of 0.53 µg/mL
(Bergogne-Berezin et al., 1994). Intravenous tobramycin has been
shown to lead to a sputum concentration of 68 µg/mL and to
show a bactericidal effect at a sputum concentrations of 25x-MIC
(Mendelman et al., 1985).
In this study, we compared the antibiotic susceptibility of
selected P. aeruginosa strains using current diagnostic methods
and our previously developed EVPL biofilm model. The increase
in bacterial resistance profile with the 1 day biofilm Calgary
device in comparison to standard MIC had been previously
reported (Macia et al., 2014). However, the Calgary device still
does not represent in vivo biofilms. Exposure to ciprofloxacin
and meropenem at concentrations higher than MBEC values and
reported sputum concentrations led to a decrease of bacterial
load by only 1–2 logs (Figure 2), which may be attributed to
the formation of denser or mature biofilm in the EVPL model
(Harrington et al., 2020). The failure to eradicate P. aeruginosa
biofilms in the EVPL model, with such high concentrations, may
be closer to the in vivo effect of these antibiotic treatments,
demonstrating the need to employ CF representative diagnostics
to better reflect on the antibiotics’ inhibitory effect.
Antibiotic tolerance was also affected by the use of different
media. Besides the difference in planktonic and biofilm based
models, Kirchner et al. (2012) demonstrated increased biofilm
inhibitory concentrations, for most tested P. aeruginosa strains,
when assessed in ASM compared with planktonic-based MIC
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in LB medium. Davies et al. (2017) also showed the increase
in bacterial heterogeneity, population diversity and antibiotic
resistance of P. aeruginosa in ASM. Therefore, we believe it is a
more accurate model to show the effect of antibiotic treatment in
CF is by testing for antibiotic susceptibility in ASM rather than
general laboratory medium. This was alarmingly poorer than in
MHB (Figure 3). As we have now demonstrated the tractability
of performing antibiotic susceptibility testing in the ex vivo lung
model using a small set of isolates. Future work can usefully assess
the antibiotic sensitivity profiles of biofilms of a much wider
range of isolates in this model and develop this model to a high
throughput method that can be easily translated into the clinic
taking advantage of its low cost.
The work also indicated the potential in vivo effect of exposure
to different antibiotics, in ASM, on the virulence of P. aeruginosa
to understand the clinical implications of chosen antibiotics.
We focused on two main virulence factors of P. aeruginosa:
proteases and pyocyanin production. Production of proteases
is triggered by the quorum sensing system to degrade vital
host proteins and antibodies. In CF lungs, proteases have been
shown to cause a severe inflammatory response leading to
pulmonary damage (Das and Manos, 2017), and were detected
in sputum during exacerbation (Jaffar-Bandjee et al., 1995).
Pyocyanin is also regulated by the quorum sensing system. It
is a redox molecule that generates reactive oxygen species to
induce oxidative stress in host cells, leading to cell damage and
lysis. This quorum sensing system is activated by the action
of antibiotics as a mechanism to persist and survive and is
cell density dependent (Singh et al., 2000; Hassan et al., 2018).
P. aeruginosa is protected from these reactive oxygen species
by its own catalases (Das and Manos, 2017). Previous studies
had estimated the concentration of pyocyanin in sputum of
as high as 16.5 µg/mL (Wilson et al., 1988), similar to the
detected values in Figure 4B. The antibiotic recovery plates
of P. aeruginosa following Calgary biofilm susceptibility testing
did not show any production of pyochelin, pyoverdine or
pyocyanin (Supplementary Figure S2), but following exposure
to antibiotics in the EVPL model, bacterial expression of
proteases and pyocyanin was increased (Figure 4). The increase
of protease/cfu and pyocyanin/cfu with combination therapy
(being normalized for the cell density) was also alarming. This
highlights the aggressiveness of P. aeruginosa infection in CF and
shows the effect different antibiotic treatments supporting the
need for anti-virulence drugs.
CONCLUSION
Bacteria causing biofilm infections are often assessed for their
antibiotic resistance profile using standard planktonic MIC
methods or simple biofilm platforms such as the Calgary device.
These do not represent the environment bacteria inhabit in vivo,
giving misleading results. The current gap in clinical outcomes
and standard susceptibility testing results is a very clear evidence.
Our results, taken from an ex vivo animal tissue model using
host-mimicking growth medium are consistent with increased
antibiotic tolerance in in vivo biofilms. It is possible that current
antibiotic prescribing could not only fail to eradicate biofilm
load, but also worsen lung conditions by increasing expression of
virulence factors by surviving bacteria, which requires immediate
action to help eradicate biofilm infections. Thus, further work
with clinical samples will be required to determine the effect of
antibiotic treatment on bacterial load, lung function, and possibly
exacerbations. It is also important to assess the role of mucoidy
and alginate production with antibiotic treatments.
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